Magzter GOLD ile Sınırsız Olun
Sadece 9.000'den fazla dergi, gazete ve Premium hikayeye sınırsız erişim elde edin
Denemek ALTIN - Özgür
Does US cancer drug nod make Cipla attractive?
Mint Chennai
|April 18, 2025
Cipla, which makes HIV, respiratory and cancer drugs, is targeting North America with generic launches
Cipla Ltd's shares have surged 6% since last week when it announced the final approval from the US Food and Drug Administration for its generic version of Bristol Myers Squibb's Abraxane, a cancer drug. Does the approval to sell the much-awaited product in the US make Cipla a compelling buy, especially when Trump's tariffs loom?
"One product approval by itself doesn't suddenly make a company more attractive," said Prashant Nair, lead analyst for pharma and healthcare at Ambit Capital. "Earlier-than-expected approval for Abraxane is positive, but tariffs will have a bearing on Cipla."
Bu hikaye Mint Chennai dergisinin April 18, 2025 baskısından alınmıştır.
Binlerce özenle seçilmiş premium hikayeye ve 9.000'den fazla dergi ve gazeteye erişmek için Magzter GOLD'a abone olun.
Zaten abone misiniz? Oturum aç
Mint Chennai'den DAHA FAZLA HİKAYE
Mint Chennai
Is America’s economy turning into a casino? Both yes and no
Americans are taking too many bad risks and too few good ones
3 mins
November 20, 2025
Mint Chennai
Global reset done, TVS supply chain unit eyes margin boost
TVS Supply Chain Solutions (SCS), whose wafer-thin margins and weak post-IPO performance have dampened investor sentiment since its 2023 debut, is looking to reset expectations after a major overhaul of its overseas operations.
2 mins
November 20, 2025
Mint Chennai
A fresh perspective on abstraction in art
A new exhibition in Mumbai showcases different approaches to abstraction by artists like Zarina, Seher Shah and Mehlli Gobhai
3 mins
November 20, 2025
Mint Chennai
A Gustav Klimt portrait shatters art records
Portrait of Elisabeth Lederer was sold at Sotheby's for $236.4 million
2 mins
November 20, 2025
Mint Chennai
Exide's dual bet: Can lithium-ion offset a weakening core?
Exide Industries Ltd is struggling to fuel its core lead-acid business while simultaneously turning its capex-heavy lithium-ion venture into a viable second growth engine.
1 mins
November 20, 2025
Mint Chennai
The crypto trades that amplified gains are now turbocharging losses
The rally in crypto prices this year was boosted by a large heap of debt, with traders using leverage to amplify their gains.
3 mins
November 20, 2025
Mint Chennai
Sebi mulls easing FPI trade settlement
The move would reduce costs for FPIs, says Sebi chairperson Tuhin Kanta Pandey.
1 min
November 20, 2025
Mint Chennai
Samsung India logs double-digit growth
Samsung India Electronics said it has clocked a double digit growth in its revenue from operations of over 11% to ₹1.11 trillion in the financial year ended March 2025.
1 min
November 20, 2025
Mint Chennai
BSNL dials vendors for a fix as regulator flags weak signal
State-owned Bharat Sanchar Nigam Ltd (BSNL) has flagged weak transmission signals at thousands of its new 4G towers—an issue behind call drops and slower data speeds—at a time when the operator is attempting a long-awaited turnaround backed by the government's successive revival packages.
1 mins
November 20, 2025
Mint Chennai
RP-Sanjiv Goenka enters luxe fashion with FSP stake buy
PSG Ventures Ltd, part of the RP-Sanjiv Goenka Group, on Wednesday approved the acquisition of a 40% stake in FSP Design Pvt. Ltd, the company behind the luxury fashion label Falguni Shane Peacock (FSP), is marking its formal entry into India’s luxury apparel and lifestyle market.
1 mins
November 20, 2025
Listen
Translate
Change font size